GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » 5-Year Yield-on-Cost %

ClearPoint Neuro (ClearPoint Neuro) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro 5-Year Yield-on-Cost %?

ClearPoint Neuro's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for ClearPoint Neuro's 5-Year Yield-on-Cost % or its related term are showing as below:



CLPT's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.17
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of ClearPoint Neuro's 5-Year Yield-on-Cost %

For the Medical Devices subindustry, ClearPoint Neuro's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClearPoint Neuro's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's 5-Year Yield-on-Cost % falls into.



ClearPoint Neuro 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of ClearPoint Neuro is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

ClearPoint Neuro  (NAS:CLPT) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


ClearPoint Neuro 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


ClearPoint Neuro (ClearPoint Neuro) Business Description

Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.
Executives
Lynnette C Fallon director 108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau director 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra officer: Chief Operating Officer 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett director, officer: CEO and President C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall officer: GM, Biologics & Drug Delivery 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro officer: Vice President, Finance 5 MUSICK, IRVINE CA 92618
Harold A Hurwitz officer: Chief Financial Officer
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R director C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards director ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc. 10 percent owner 75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners officer: Vice President, Marketing ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103

ClearPoint Neuro (ClearPoint Neuro) Headlines

From GuruFocus

ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023

By sperokesalga sperokesalga 04-28-2023

ClearPoint Neuro Announces Receipt of MDSAP Certification

By GuruFocusNews GuruFocusNews 06-22-2022